Natural Killer Cells Play Role in Ability of CML Patients to Discontinue TKIs

Patients with CML who have higher proportions of natural killer immune cells, and more mature natural killer cells, fare better when discontinuing therapy with imatinib.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Chronic Myeloid Leukemia Hematologic Malignancies & Lymphoma News Source Type: news